Download
10334_2024_Article_1192.pdf 1,11MB
WeightNameValue
1000 Titel
  • Assessment of hepatic transporter function in rats using dynamic gadoxetate-enhanced MRI: a reproducibility study
1000 Autor/in
  1. Gunwhy, Ebony |
  2. Hines, Catherine D. G. |
  3. Green, Claudia |
  4. Laitinen, Iina |
  5. Tadimalla, Sirisha |
  6. Hockings, Paul D. |
  7. Schütz, Gunnar |
  8. Kenna, J. Gerry |
  9. Sourbron, Steven |
  10. Waterton, John C. |
1000 Verlag Springer International Publishing
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-08-06
1000 Erschienen in
1000 Quellenangabe
  • 37(4):697-708
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s10334-024-01192-5 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11417070/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:sec> <jats:title>Objective</jats:title> <jats:p>Previous studies have revealed a substantial between-centre variability in DCE-MRI biomarkers of hepatocellular function in rats. This study aims to identify the main sources of variability by comparing data measured at different centres and field strengths, at different days in the same subjects, and over the course of several months in the same centre.</jats:p> </jats:sec><jats:sec> <jats:title>Materials and methods</jats:title> <jats:p>13 substudies were conducted across three facilities on two 4.7 T and two 7 T scanners using a 3D spoiled gradient echo acquisition. All substudies included 3–6 male Wistar-Han rats each, either scanned once with vehicle (<jats:italic>n</jats:italic> = 76) or twice with either vehicle (<jats:italic>n</jats:italic> = 19) or 10 mg/kg of rifampicin (<jats:italic>n</jats:italic> = 13) at follow-up. Absolute values, between-centre reproducibility, within-subject repeatability, detection limits, and effect sizes were derived for hepatocellular uptake rate (<jats:italic>K</jats:italic><jats:sup>trans</jats:sup>) and biliary excretion rate (<jats:italic>k</jats:italic><jats:sub>bh</jats:sub>). Sources of variability were identified using analysis of variance and stratification by centre, field strength, and time period.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>Data showed significant differences between substudies of 31% for <jats:italic>K</jats:italic><jats:sup>trans</jats:sup> (<jats:italic>p</jats:italic> = 0.013) and 43% for <jats:italic>k</jats:italic><jats:sub>bh</jats:sub> (<jats:italic>p</jats:italic> &lt; 0.001). Within-subject differences were substantially smaller for <jats:italic>k</jats:italic><jats:sub>bh</jats:sub> (8%) but less so for <jats:italic>K</jats:italic><jats:sup>trans</jats:sup> (25%). Rifampicin-induced inhibition was safely above the detection limits, with an effect size of 75 ± 3% in <jats:italic>K</jats:italic><jats:sup>trans</jats:sup> and 67 ± 8% in <jats:italic>k</jats:italic><jats:sub>bh</jats:sub>. Most of the variability in individual data was accounted for by between-subject (<jats:italic>K</jats:italic><jats:sup>trans</jats:sup> = 23.5%; <jats:italic>k</jats:italic><jats:sub>bh</jats:sub> = 42.5%) and between-centre (<jats:italic>K</jats:italic><jats:sup>trans</jats:sup> = 44.9%; <jats:italic>k</jats:italic><jats:sub>bh</jats:sub> = 50.9%) variability, substantially more than the between-day variation (<jats:italic>K</jats:italic><jats:sup>trans</jats:sup> = 0.1%; <jats:italic>k</jats:italic><jats:sub>bh</jats:sub> = 5.6%). Significant differences in <jats:italic>k</jats:italic><jats:sub>bh</jats:sub> were found between field strengths at the same centre, between centres at the same field strength, and between repeat experiments over 2 months apart in the same centre.</jats:p> </jats:sec><jats:sec> <jats:title>Discussion</jats:title> <jats:p>Between-centre bias caused by factors such as hardware differences, subject preparations, and operator dependence is the main source of variability in DCE-MRI of liver function in rats, closely followed by biological between-subject differences. Future method development should focus on reducing these sources of error to minimise the sample sizes needed to detect more subtle levels of inhibition.</jats:p> </jats:sec>
1000 Sacherschließung
lokal Chemical and drug induced liver injury
lokal Basic Science - Preclinical imaging
lokal Liver/metabolism [MeSH]
lokal Rats [MeSH]
lokal Rifampin/pharmacology [MeSH]
lokal Animals [MeSH]
lokal Contrast Media [MeSH]
lokal Gadolinium ethoxybenzyl DTPA
lokal Rats, Wistar [MeSH]
lokal Male [MeSH]
lokal Reproducibility of Results [MeSH]
lokal Rats
lokal Reproducibility of results
lokal Magnetic resonance imaging
lokal Magnetic Resonance Imaging/methods [MeSH]
lokal Gadolinium DTPA/pharmacokinetics [MeSH]
lokal Research Article
lokal Liver/diagnostic imaging [MeSH]
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-5608-9812|https://frl.publisso.de/adhoc/uri/SGluZXMsIENhdGhlcmluZSBELiBHLg==|https://frl.publisso.de/adhoc/uri/R3JlZW4sIENsYXVkaWE=|https://frl.publisso.de/adhoc/uri/TGFpdGluZW4sIElpbmE=|https://frl.publisso.de/adhoc/uri/VGFkaW1hbGxhLCBTaXJpc2hh|https://frl.publisso.de/adhoc/uri/SG9ja2luZ3MsIFBhdWwgRC4=|https://frl.publisso.de/adhoc/uri/U2Now7x0eiwgR3VubmFy|https://frl.publisso.de/adhoc/uri/S2VubmEsIEouIEdlcnJ5|https://frl.publisso.de/adhoc/uri/U291cmJyb24sIFN0ZXZlbg==|https://frl.publisso.de/adhoc/uri/V2F0ZXJ0b24sIEpvaG4gQy4=
1000 Hinweis
  • DeepGreen-ID: 7224c57393e64b7eb878506846889ea6 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Innovative Medicines Initiative |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Innovative Medicines Initiative |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6508448.rdf
1000 Erstellt am 2025-02-06T17:24:05.779+0100
1000 Erstellt von 322
1000 beschreibt frl:6508448
1000 Zuletzt bearbeitet 2025-09-14T01:13:47.699+0200
1000 Objekt bearb. Sun Sep 14 01:13:47 CEST 2025
1000 Vgl. frl:6508448
1000 Oai Id
  1. oai:frl.publisso.de:frl:6508448 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source